Connection

SARAH WOODFIELD to Drug Synergism

This is a "connection" page, showing publications SARAH WOODFIELD has written about Drug Synergism.
Connection Strength

0.171
  1. Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling. Cancer Lett. 2019 08 10; 457:129-141.
    View in: PubMed
    Score: 0.038
  2. Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma. Mol Cancer Ther. 2019 06; 18(6):1045-1056.
    View in: PubMed
    Score: 0.038
  3. TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis. Oncotarget. 2017 May 16; 8(20):33666-33675.
    View in: PubMed
    Score: 0.034
  4. Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine. Sci Rep. 2016 06 10; 6:27458.
    View in: PubMed
    Score: 0.031
  5. Sensitivity of neuroblastoma to the novel kinase inhibitor cabozantinib is mediated by ERK inhibition. Cancer Chemother Pharmacol. 2015 Nov; 76(5):977-87.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.